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Abstract  
Objective: The temporal relationship between white matter (WM) and grey matter 
(GM) damage in vivo in early primary-progressive multiple sclerosis (PPMS) was 
investigated testing two hypotheses: (i) WM tract abnormalities predict 
subsequent changes in the connected cortex (“primary WM damage model”); and 
(ii) cortical abnormalities predict later changes in connected WM tracts (“primary 
GM damage model”).  
 
Methods: Forty-seven early PPMS patients and 18 healthy controls (HC) had 
conventional and magnetisation transfer (MT) imaging at baseline; a subgroup of 
35 patients repeated the protocol after 2 years. Masks of the cortico-spinal tracts, 
genu of the corpus callosum and optic radiations (OR) and of connected cortical 
regions were used for extracting the mean MT ratio (MTR). Multiple regressions 
within each of five tract-cortex pairs were performed, adjusting for the dependent 
variable's baseline MTR; tract lesion load and MTR, spinal-cord area, age and 
gender were examined for potential confounding. 
 
Results: The baseline MTR of most regions was lower in patients than HC. The 
tract-cortex pair relationships in the “primary WM damage model” were significant 
for the bilateral motor pair and right visual pair, while those in the "primary GM 
damage model" were only significant for the right motor pair. Lower lesion MTR 
at baseline was associated with lower MTR in the same tract NAWM at 2-year in 
three tracts. 
 
Conclusion:  These results are consistent with the hypothesis that in early PPMS 
cortical damage is for the most part a sequela of NAWM pathology, which, in 
turn, is predicted by abnormalities within WM lesions.  
 
  
 
Introduction:  
 
Little is known about the pathological relationship linking white matter (WM) and 
grey matter (GM) damage in multiple sclerosis (MS). Post-mortem studies 
provide a snapshot of pathology in WM and GM, and have demonstrated 
demyelination and neuro-axonal damage in both tissues1-6. However, a key 
question is to what extent pathological abnormalities in the GM are related to 
contiguous WM damage, either as a cause or consequence, or are the result of 
independent disease mechanisms. Longitudinal MRI studies represent a valuable 
approach to explore the dynamic associations between WM and GM pathology. 
Patients with early PPMS should be an informative group in which to explore this 
question, as brain MRI lesion load is smaller compared with relapse-onset MS.  
 
We have previously investigated in early PPMS the spatial relationship between 
pathology in WM tracts and connected GM areas using cross-sectional MRI 
data7. We found that in some brain regions, pathology in WM tracts is correlated 
with that in the adjacent GM regions7.  
 
Here we sought to determine if (i) pathology in WM tracts is associated with (i.e. 
“predicts”) subsequent changes in connected cortical GM (“primary WM damage 
model”) or (ii) pathology in cortical GM is associated with (i.e. “predicts”) 
subsequent changes in the connected normal-appearing (NA)WM tracts 
(“primary GM damage model”) in early PPMS, recognising that both may occur 
simultaneously perhaps with one dominating. We also investigated the 
relationship between tract-specific lesions at baseline and NAWM/GM 
abnormalities changes over time. Microstructural changes were assessed using 
Magnetization Transfer Ratio (MTR), as lower MTR has been shown to reflect 
demyelination and neuronaxonal loss in MS8,9. 
 
 
 
  
 
Methods:   
 
Subjects and study design 
MRI and clinical data, including the Expanded Disability Status Scale (EDSS) 
scores10 from 47 people with definite or probable PPMS11, no other known 
neurological condition, and a history of clinical progression of less than 5 years, 
were analysed in this study (Table 1). All patients had MR imaging at baseline, 
while a subgroup of 35 patients repeated the imaging protocol 24 months later 
(mean time interval 24.5 months, standard deviation (SD) 1.5). The MRI scans of 
four out of these 35 patients were unusable because of movement artefacts. A 
group of 18 healthy subjects (included if in good general health, no known history 
of medical conditions known to affect the brain, and without contraindications to 
MRI scanning) underwent the same imaging protocol (Table 1).  
 
Standard Protocol Approvals, Registrations, and Patient Consents 
This work was approved by the Joint Medical Ethics Committee of the National 
Hospital for Neurology and Neurosurgery and the UCL Institute of Neurology, 
London, and written informed consent was obtained by all participants.  
 
Image Acquisition  
Imaging was performed using a 1.5-T GE Signa scanner (General Electric, 
Milwaukee, IL). At baseline and 24 months, all subjects had a three-dimensional 
inversion-prepared fast spoiled gradient recall (3D-FSPGR) T1-weighted (T1-w) 
sequence of the brain, and a fast spin echo scan (i.e., proton-density-weighted 
(PD-w) and T2-weighted (T2-w) scans), and a magnetisation transfer (MT) dual 
echo interleaved spin-echo sequence (details on MRI sequences are given in the 
Supplementary Material). In the PPMS groups, a fast‐spoiled gradient echo of 
the spinal cord was performed; a series of five contiguous 3mm axial slices 
(perpendicular to the spinal cord) were reformatted using the centre of the C2/C3 
disc as the caudal landmark.  
 
To generate a set of tract and associated cortical GM templates, spin echo 
diffusion-weighted (DW) echo planar imaging scans were obtained from a 
separate group of 23 healthy controls (12 women; mean age 35.1 years, SD 7.9). 
 
Image analysis 
 
Using the method described by Tozer et al.12, templates for the following WM 
tracts and their associated cortical GM were derived (Figure 1A):  
 
1) The left and right motor pair (composed of cortico-spinal tract (CST) 
and connected GM in the pre- and post-central cortex); 
2) The callosal pair (consisting of the genu of the corpus callosum (CC) 
and its connected GM region in the frontal lobe); 
3) The left and right visual pair (composed of the optic radiation (OR) and 
its connected GM area in the visual cortex).  
 Using the baseline and 24-month MRI data from the PPMS and control groups, 
native space MTR maps were calculated13. Tract-cortex pair templates were 
transformed into native space12 (Figure 1B) and visually checked for registration 
errors, allowing WM tract and associated cortical GM MTR to be determined. In 
the PPMS group, WM lesions were delineated on the PD images, and lesions 
masks were binarised. The PD/T2-weighted scans were co-registered to the 
MTR maps and associated lesion masks moved into native MTR space.  The 
WM lesion masks were subtracted from the WM component of each tract-cortex 
pair at each time-point, so leaving NAWM. In the PPMS group, the total volume 
of the each WM tract (including lesions and NAWM) and associated cortical GM 
regions were calculated computing the number of voxel for each region, and 
tract-cortex specific NAWM and GM mean MTR values determined. Except for 
lesion volumes, the same measures were derived from the healthy control data. 
 
Since spinal cord damage is thought to play an important role in the 
pathogenesis of PPMS14, in the patient group, the cord cross-sectional area at 
the C2-3 level was calculated as previously described15. 
 
Statistics 
Changes in EDSS between baseline and two years were assessed using the sign 
test.  
 
Differences in mean MTR and volume between patients and controls at baseline 
and 24 months in WM tracts and cortical GM regions were assessed using 
multiple regressions, with age and gender as covariates.  Where regression 
residuals showed deviations from normality and homoscedasticity (all relatively 
minor), a non-parametric bias-corrected and accelerated bootstrap16 was 
performed (1000 replicates).  Where a potentially influential datapoint was 
identified, bootstrapped regression was repeated omitting it. In the PPMS group 
changes in mean MTR of the WM lesions, the NAWM, and the connected GM 
area from baseline to 24 months, were tested for using one-sample t-tests. 
Univariable (pairwise) associations between MTR values in each tract pair were 
assessed with Pearson correlation, and the effect of omitting potentially influential 
datapoints explored.  To assess cross-sectional associations between WM and 
GM pathology in the PPMS group, multiple regression was used between each 
tract-cortex pair’s NAWM mean MTR and the corresponding GM region mean 
MTR; age, gender, disease duration, NAWM and GM volumes, tract-specific 
lesion MTR and volume, and spinal-cord area were separately included (because 
of the relatively small number of patients) as potentially confounding covariates.  
 
To assess the temporal relationship between tract-specific NAWM and GM value, 
we tested two models in each tract-cortex pair: (i) the “primary WM damage 
model”, to examine if early NAWM MTR predicts late GM MTR; (ii) the “primary 
GM damage model”, to examine if early GM MTR predicts late NAWM MTR. In 
order to enable joint testing (to reduce the number of tests), and to permit direct 
testing of the primary WM versus GM models, these models were implemented 
with multivariate regressions: for (i), the “primary WM damage model”, five 
simultaneous regressions (for each of the five tracts) regressed the 24-month GM 
MTR outcome on the tract-specific baseline NAWM MTR predictor; the 
corresponding tract-specific baseline GM MTR was a covariate for each 
regression, to ensure that any baseline NAWM versus 24-month GM association 
was not explained by cross-sectional baseline NAWM versus GM association, 
which could induce the longitudinal association without prior WM damage.  The 
null hypothesis, that baseline was not associated with 24-month MTR in any of 
the tracts, was jointly tested as a single hypothesis that all five baseline MTR 
coefficients (one in each regression), were zero. For (ii), the “primary GM 
damage model”, the simultaneous regressions used 24-month NAWM MTR with 
tract-specific baseline GM MTR predictors, adjusting for corresponding baseline 
NAWM MTR. To examine whether age, gender, disease duration, NAWM or GM 
global volumes, tract-specific lesion MTR or volume, or spinal cord area 
explained the associations, these were included singly as covariates in each tract 
regression. The role of early lesions in contributing to later NAWM or GM 
damage was assessed when tract-specific baseline lesion volume was included 
in the (i) and (ii) multivariate models above. 
 
Analyses were performed in Stata 13 (Stata Corporation, College Station, Texas, 
USA); the multivariate regressions were carried out using the Stata structural 
equation modeling (SEM) command, using, as estimation method, maximum 
likelihood with missing values; this requires the assumptions of multivariate 
normality, and that the mechanism for missing data is either completely at 
random or associated with variables in the model.  Results are reported as 
significant at p<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Clinical assessment  
 
Patients clinically deteriorated over the follow-up period (baseline: median EDSS 
4.5, range 1.5-7; two years: median EDSS 6, range 1.5-8; p=0.017). 
 
Baseline difference in MTR and volume between patients and healthy controls 
and MTR evolution over the follow-up 
 
At baseline, patients showed reduced MTR in the NAWM of the bilateral CST 
compared to controls, but did not differ significantly in the GM MTR of the 
connected motor cortex (Table 2, e-Figure 1). Patients showed significantly 
lower MTR than controls at baseline in the callosal tract and connected cortex, 
and in the right OR and bilateral visual cortex (Table 2, e-Figure 1). Regional 
differences in NAWM and GM volume between patients and controls at baseline 
are reported in e-Table 1. 
 
In patients, a statistically significant decrease in mean MTR over 24 months was 
seen in the GM of the left visual cortex (percentage of change in MTR over time= 
-1.27%, p=0.045), while a trend towards a significant decrease over the follow-up 
was found in the GM of the right visual cortex (percentage of change in MTR over 
the follow-up = -0.89%, p=0.051) (e-Table 2). 
 Correlation between WM and GM MTR at each time-point 
 
In the patient group at baseline, a lower mean MTR of each tract’s NAWM was 
significantly associated with a lower mean MTR of the corresponding GM target 
in the left motor pair (r=0.36, p=0.014), in the callosal pair (r=0.56, P<0.001)  and 
in the left and right visual pair (both r=0.53, p<0.001), but not in the right motor 
pair (r=0.17, p=0.260).  When adjusting for potential confounders, these 
associations remained significant for the callosal and the visual pairs.  
At 24 months, a lower mean MTR of each tract was associated with a lower 
mean MTR of the corresponding GM region in all tract-cortex pairs independently 
of all the other covariates, except for the left motor pair when adjusting for 
baseline whole WM MTR (e-Figure 2).  
 
The “primary WM damage model” 
 
The joint test for the “primary WM damage model” gave p=0.006, rejecting the 
hypothesis of no association in any of the tracts: specifically, a lower baseline 
MTR of tract NAWM was associated with lower GM MTR of the connected cortex 
at 24 months in the bilateral motor pair and in the right visual pair, adjusting for 
tract-specific baseline GM  MTR (Table 3A, Figure 2, e-Figure 2). The inclusion 
of age, gender, disease duration, baseline NAWM and GM volumes, baseline 
lesion MTR and lesion volume, and baseline spinal cord area in the model did not 
materially alter the results. 
 
The “primary GM damage model” 
 
In the “primary GM damage model”, although the joint test was again significant 
(p=0.007), this was driven by a single significant association in the right motor 
cortex, where a lower baseline GM MTR predicted higher right CST MTR at 24 
months after adjusting for baseline NAWM tract MTR (Table 3B, Figure 2, e-
Figure 2). When including age, gender, disease duration, baseline NAWM and 
GM volumes, baseline lesion MTR and lesion volume, and baseline spinal cord 
area in the model, results did not change materially.  
 
Correlation between lesional metrics at baseline and tissue damage at two years 
 
In all tract-cortex pairs, no significant association was found between tract-
specific lesion MTR and volume at baseline, and the corresponding cortical 
region’s GM MTR at 24 months. Lower tract-specific lesion MTR at baseline was 
associated with lower MTR in the same tract NAWM at 24 months in all tracts, 
except the visual tracts bilaterally.  
 
 
 Discussion 
 
Our results are consistent with an evolving relationship between anatomically 
linked GM and WM pathology in early PPMS. WM changes appear to predict 
subsequent GM abnormalities, more so than GM abnormalities predict 
subsequent WM damage. Over the two years of observation, abnormalities in 
NAWM rather than the WM lesions appeared to have a greater association with 
later GM damage. Over the same period, baseline WM lesion measures 
predicted subsequent changes in NAWM. Overall, this is consistent with a 
sequence of events, unfolding over two or more years, arising from WM lesions, 
through NAWM change, and leading to subsequent GM abnormalities. 
 
At baseline, MTR in NAWM tracts was significantly lower in patients than in 
healthy controls (i.e. CST, GCC and OR) and in the corresponding GM targets, 
with the exception of the left OR and the motor cortex bilaterally, consistent with 
previous findings in this same cohort7,17-19. The relative sparing of motor cortex is 
in line with previous MTR studies on patients with relapsing-remitting MS20,21. 
Cross-sectional correlations between NAWM and GM damage at each time-point 
were significant in all tract-cortex pairs, except in the right motor tract-cortex-pair, 
confirming our previous results7, which indicate that pathological processes 
affecting the two compartments are correlated. Allowing for these baseline tract-
cortex associations, statistical tests of the “primary WM damage model” was 
more consistently and robustly significant than those testing the “primary GM 
damage model”. Interestingly, baseline T2-w lesion load did not materially alter 
the models, i.e. that over the two years of observation GM changes were mostly 
related to NAWM abnormalities rather than lesions. However, baseline T2-w 
lesion load was associated with subsequent NAWM abnormalities, and so the 
ultimate consequence of lesion formation may include cortical changes, albeit 
taking more than two years to become manifest. 
 
Axons are the cellular component linking WM lesions, WM tracts and cortical GM, 
and axonal degeneration in WM lesions22 and NAWM23, could well be the 
initiating element leading to subsequent cortical neuronal pathology3,24. Several 
mechanisms within WM may contribute towards axonal pathology including 
glutaminergic excitotoxicity, disrupted intra-axonal transport, and mitochondrial 
dysfunction3. It has also been suggested that the pathogenesis of PPMS, when 
compared with relapse-onset disease, is primarily one of cellular degeneration, 
and that this may begin years before the first onset of symptoms25. This would 
provide a plausible mechanism connecting a primary WM axonal pathology with 
a subsequent neuronal loss in the connected GM areas. 
 
When the “primary GM damage model” was tested, the only significant finding 
was the association in the right motor pair between lower baseline MTR in the 
right motor cortex and the higher MTR in the right CST at 24 months; this 
association, is not consistent with a “primary GM damage” hypothesis. In any 
case, it is possible that this correlation was induced by an outlying data point. It 
should be noted that this study specifically recruited people with clinically early 
PPMS, and our results may not be applicable to people with long standing 
progressive MS. There is increasing evidence from histopathology and imaging 
studies that suggests that a substantial proportion of GM pathology, in particular 
subpial demyelination and cortical neurodegeneration, develops independently of 
WM damage26,27,28: This component of GM damage is thought to be influenced 
by meningeal inflammation, which is particularly prominent in long-standing 
progressive MS29-30. As such, it is possible that a ‘’primary GM damage model’’ 
may play a more substantial role later on in PPMS. 
 
While we have interpreted our results as being consistent with tract-mediated 
processes, they could also represent coincident but independent development of 
regional pathology, with pathological changes in NAWM and GM progressing at 
similar rate. However, in this case it would then be expected to see baseline GM 
MTR predicting subsequent NAWM MTR in the same tract-cortex pairs in which 
the “primary WM damage model” was significant, but only in one of the three 
significant pairs did we find this. Our results do not exclude the possibility of both 
dependent and independent components working in parallel, with one prevailing 
over the other at different stages of disease or in different brain regions. Further 
results from longer longitudinal studies, investigating the dynamics of WM and 
GM changes in a larger number of brain regions, are needed to confirm and 
generalise our conclusions, which should be interpreted with caution also in light 
of the amount of missing values at 24 months. To reduce the impact of missing 
MTR values, we relied on multivariate normality and ‘missing-at-random’ 
assumptions ,which allowed all available data points to be used. While there was 
no evidence to suggest violation of these assumptions, they are inherently 
difficult to assess. 
 
Given the challenges of gathering large clinical and MRI datasets, we used 
previously acquired data for this work. Inaccuracies in tract alignment with 
cortical targets (and so associated partial volume effects) could have limited our 
sensitivity to tract-cortex associations. Sequences tuned to detect GM lesions 
were not available when these data were collected, and unseen GM lesions are 
likely to increase the variability of GM MTR across subjects, and therefore further 
decrease our sensitivity to finding associations in the “primary WM” damage 
model. As this was a retrospective study, we were limited in our scope to select 
healthy control scan data obtained over a comparable time period, giving rise to 
relatively poor matching with older MS subjects.  Although there was very little 
evidence of an association between age or gender and MTR values, the patient 
versus healthy control adjusted differences may still have been influenced in part 
by this age distribution mismatch. Moreover, some MTR values lying in the tails 
of the data influenced the strength and significance of some correlations. As 
such, the results from this dataset should be interpreted with due caution, and 
further studies, informed by our methods, are required to clarify the actual 
strength of associations in the tract-cortex pairs.   
 
In conclusion, our results in patients with early PPMS suggest a temporal 
evolution of pathology from WM to GM, and more specifically, from lesions to 
NAWM and from NAWM to GM. 
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Figure legends 
 
Figure 1. Reconstruction of the five tract-cortex pairs 
A. The left and right motor pair (composed of CST and connected GM in the pre- 
and post-central cortex, voxels in blue), the callosal pair (voxels in yellow, 
consisting of the genu of the CC and its connected GM region in the frontal lobe) 
and the left and right visual pair (voxels in red, composed of OR and its 
connected GM area in the visual cortex), reconstructed from the DTI control 
group in standard space. B. Left and right CST (voxels in red), and associated 
voxels in the precentral/postcentral cortex (voxels in blue) in a single patient, 
overlaid onto the patient’s T1-w image in native space. 
 
Figure 2. Tract-specific associations between baseline and 24-month MTR 
values. 
In these panels are reported the six scatter plots between the four MTR 
measures (baseline NAWM and GM, 24-month NAWM and GM) for the right 
motor tract-cortex pair.  The 24m GM against baseline NAWM and 24m NAWM 
against baseline GM are the unadjusted pairwise versions of the ‘’primary WM 
damage’’ and ‘’primary GM damage” models for this tract-cortex pair.  
 
Tables and table legends 
Table 1 
 
 
Characteristics Patients Healthy Controls 
Number 47 18 
Age, years (mean (SD)) 43.9 (11.2) 35.2 (6.02) 
Gender, female/male 18/29 11/7 
Disease duration, years (mean (SD)) 3.4 (0.9) - 
EDSS, median (range) 4.5 (1.5-7) - 
T2 lesion load, ml (mean (SD)) 15.4 (17.3) - 
Spinal cord area, mm2 (mean (SD)) 70.3 (9.4) - 
 
 
Table 1. Demographic, clinical and radiological characteristics of patients and 
healthy controls at study entry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 
 
 
 
 NAWM 
patients 
 
mean (SD) 
MTR 
 
WM 
controls 
 
mean (SD) 
MTR 
p-values 
 
 
patients 
vs 
controls 
GM 
patients 
 
mean (SD) 
MTR 
GM 
controls 
 
mean (SD) 
MTR 
p-values 
 
 
patients 
vs 
controls 
Motor pair 
 
 Left 
 
 Right 
 
 
 
36.2 (1.4) 
 
36.1 (1.3) 
 
 
37.2 (0.59) 
 
37.0 (0.66) 
 
 
p=0.002 
 
p=0.006 
 
 
35.1 (2.4) 
 
33.9 (2.5) 
 
 
35.7 (1.2) 
 
35.3 (1.8) 
 
 
p=0.392 
 
p=0.235 
Callosal pair      
  38.1 (1.7) 
 
39.5 (0.46) 
 
 p<0.001 
     
  32.4 (1.3) 
     
33.6 (0.97) 
 
p=0.004 
Optic pair 
 
 Left 
 
 Right 
 
 
34.1 (2.0) 
 
34.4 (1.9) 
 
 
35.5 (1.4) 
 
36.1 (0.85) 
 
 
 p=0.080b 
 
 p=0.002 
 
 
31.2 (1.7) 
 
32.2 (1.4) 
 
 
32.6 (1.4) 
 
33.6 (0.94) 
 
 
p=0.011a,b 
 
p=0.001 
 
 
 
a
This comparison lost significance when an influential datapoint was omitted. 
b
Under a crude Bonferroni correction, multiplying all p-values by the number of tests, these two p-values are no longer 
significant at the 5% error rate.
 
 
 
Table 2. Mean MTR values at baseline in GM and WM regions in patients and 
healthy controls, with p-values of the comparison between the two groups 
adjusting for age and gender. 
 
 
 
Table 3 
 
A.  
 
Tract-cortex pairs Baseline WM MTR 
standardised 
regression coefficient † 
95% 
confidence 
interval 
P-value Partial 
correlation 
coefficients 
 
 
 
WM       GM   
Left motor pair 0.32 0.03, 0.60 P=0.031 0.40 0.53 
Right motor pair 0.47 0.21, 0.72 P<0.001 0.45 0.36 
Callosal pair -0.25 -0.60, 0.10 P=0.161 -0.12 0.67 
Left visual pair 0.08 -0.15, 0.31 P=0.476 0.22 0.82 
Right visual pair 0.22 0.01, 0.43 P=0.036 0.33 0.83 
 
† The standard regression coefficient reported is the number of standard deviations by which  
24m GM MTR is estimated to increase per one standard deviation increase in baseline WM MTR. 
 
B.  
 
Tract-cortex  
pair 
Baseline GM MTR 
standardised 
regression coefficient 
† 
95% confidence 
interval 
P-value Partial 
correlation 
coefficient 
 
 
 
WM       GM 
Left motor pair -0.08 -0.20, 0.04 P=0.218 0.77 -0.56 
Right motor pair -0.28 -0.44, -0.12 P=0.001 0.71 -0.62 
Callosal pair -0.03 -0.22, 0.17 P=0.800 0.82 -0.30 
Left visual pair 0.08 -0.06, 0.23 P=0.237 0.89 0.16 
Right visual pair 0.17 -0.07, 0.41 P=0.172 0.83 0.31 
 
† The standard regression coefficient reported is the number of standard deviations by which 24m 
WM MTR is estimated to increase per one standard deviation increase in baseline GM MTR 
 
Table 3: A. Standardised regression coefficients for the “primary WM damage” 
multivariate model, where, for each of the five pairs, 24-month GM MTR is 
regressed on the tract-specific baseline NAWM MTR predictor, adjusting for the 
corresponding tract-specific baseline GM MTR. B. Standardised regression 
coefficients for the “primary GM damage” multivariate model, where, for each of 
the five pairs, 24-month WM MTR is regressed on the tract-specific baseline GM 
MTR predictor, adjusting for the corresponding tract-specific baseline NAWM 
MTR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Electronic Figure 1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Electronic Figure 1: Box plots of baseline MTR values in the five tract-cortex 
pairs in patients and healthy controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Electronic Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E-figure 2 In these panels are reported the six scatter plots between the four 
MTR measures (baseline NAWM and GM, 24-month NAWM and GM) for the left 
motor, callosal, and visual tract-cortex-pairs.  The 24m GM against baseline 
NAWM and 24m NAWM against baseline GM are the unadjusted pairwise 
versions, for each tract-cortex pair, of the ‘’primary WM damage’’ and ‘’primary 
GM damage” models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Electronic table 1 
 
Region Side 
NAWM volume GM volume 
MS Control p-value MS Control p-value 
Motor 
pair 
Left 209.5 (50.1) 
254.8 
(29.2) P<0.001 
32.8 
(12.5) 
41.3 
(15.3) P=0.176 
Right 225.2 (53.3) 
251.8 
(39.6) P<0.027 
40.2 
(12.8) 
46 
(14.5) P=0.120 
Callosal 
pair NA 
454.2 
(119.0) 
862.3 
(80.9) P<0.001 
292.1 
(64.4) 
526.2 
(98.3) P<0.001 
Optic pair 
Left 250.9 (66.2) 
278.5 
(47) P=0.051 
346.3 
(55.8) 
351.2 
(66.7) P=0.791 
Right 576.7 (147.0) 
686.3 
(80.7) P=0.002   
716.9 
(114.3) 
705.9 
(85.3) P=0.801 
 
 
Electronic table 1. Baseline mean (SD) volume values in NAWM and GM 
regions in patients and healthy controls, with p-values of the comparison between 
the two groups (obtained with multiple regression analyses adjusted for age and 
gender). 
 
 
 
 
 
Electronic Table 2 
 
 
 
Region Side NAWM 
 
Absolute mean 
MTR change, SD*, 
pu (% change in 
mean MTR) 
 
 
 
0-24 months 
 
p-values 
p_values for mean 
MTR change, 
(confidence 
interval) 
 
 
 
0-24 months 
WM lesions 
 
Absolute mean 
MTR change, 
SD*, pu 
(% change in 
mean MTR ) 
 
 
0-24 months 
 
p-values 
p_values for 
mean MTR   
change, 
(confidence 
interval) 
 
 
0-24 months 
GM 
 
Absolute mean 
MTR change, 
SD*, pu 
(% change in 
mean MTR ) 
 
 
 
0-24 months 
 
 
 
p-values 
p-value for 
mean MTR   
change, 
(confidence 
interval) 
 
 
 
0-24 months  
Motor pair 
 
 
 
Left 
 
 
 
 
Right 
 
 
-3.8, 59.9, (0.10%) 
 
 
 
-5.1, 97.1, (-0.14%) 
 
 
0.728,(26.2,18.52) 
 
 
 
0.773, (-41.4, 31.1) 
 
 
+39.6,178.5,(+1.3%) 
 
 
 
+82.5, 215.7,(-2.53%) 
 
 
0.359,(-49,1,128.4) 
 
 
 
0.134,(-193.4,28.4) 
 
 
-69.1,278.3,(-1.85%) 
 
 
 
-78.9, 370.1,(-1.97%) 
 
 
0.45,(-216.12,102.6) 
 
 
 
  
0.253,(-217, 59.3) 
Callosal 
pair 
NA  
+14.1,75.8,(+0.40%) 
 
0.344, (-15.9, 44.1) 
     
+7.9, 209.3, (+0.34%) 
 
0.852, (-78.5, 94.3) 
 
-21.6, 110.9, (-0.63%) 
 
0.322, (-65.4, 22.3) 
Visual pair 
 
 
 
Left 
 
 
 
 
Right 
 
 
-18.1, 105.7,(-0.57%) 
 
 
 
+10.0, 100.3, (+0.32%) 
 
 
p=0.382, (-59.9, 23.7) 
 
 
0.609, (-29.7, 49.7) 
 
 
-54.6, 262.5 (-1.49%) 
 
 
 
-27.4, 180.2, (-0.87%) 
 
 
0.329, (168.1,58.9) 
 
 
 
0.473, (105.4,50.5) 
 
 
-39.8, 98.0, (-1.27%) 
 
 
 
-29.4, 75.6 (-0.89%) 
 
 
0.045, (-78.6, -1) 
 
 
 
0.051, (-58.9, 0.13) 
 
 
*SD of the MTR change 
 
Electronic Table 2. Absolute and percentage change of mean MTR values in 
NAWM, WM lesions and GM in patients over the follow-up period, with p-values 
testing for significant change. Due to the number of tests and the borderline 
significance, the two borderline p-values should be interpreted with caution. 
 
 
Supplementary Material  
 
 
MRI Sequences 
 
Brain: 
 
1. Three-dimensional inversion-prepared fast spoiled gradient recall T1-
weighted (T1-w) sequence:  field of view (FOV) 300 x225 mm2, matrix size 
256 x160, reconstructed to 256x256 for a final in plane resolution of 1.17 
mm, 124 axial slices, 1.5-mm thickness;  
2. Fast spin echo scan that collects a proton-density-weighted (PD-w), a T2-
weighted (T2-w), and a magnetisation transfer (MT) dual echo interleaved 
spin-echo sequence: FOV 240x180 mm2, matrix size 256x256, 28 axial 
slices, 5-mm thickness; 
3. Spin echo diffusion-weighted (DW) echo planar, whole-brain and cardiac-
gated imaging scans FOV 240x240 mm2, matrix size 96x96 
(reconstructed to 128x128), image resolution 2.5x2.5x3 mm3 
(reconstructed to 1.9x1.9x3 mm3), TE 95 ms, TR 7 RRs, maximum b-
factor 1000 smm-2; three series, each collecting 14 axial slices of 3-mm 
thickness, which were interleaved off-line; diffusion gradients were applied 
along 25 optimized directions, and three images with no diffusion 
weighting were also acquired. 
 
Spinal cord: 
1. Inversion prepared gradient echo : 60 1‐mm slices, TR = 15.6 ms, TE = 4.2 
ms, inversion time (TI) = 450 ms, FA 20°, matrix 256 × 256.  
Appendix I 
 
Description of missing values 
 
 
Of the 10 MTR variables in the model (WM and GM in 5 tract-cortex pairs): at 
baseline, MTR data was missing for only one out of the 47 MS patients, and for 
the rest of the group all 10 MTR figures were available; at 24 months, in 3 MS 
patients 6 variables were missing for the callosal and visual pairs (due to 
suboptimal image registration). Sixteen patients had missing values in all ten 
variables: 1) four of these had MRI scans at 24 months but the images were 
unusable because of movement artifacts; it is plausible, though of course 
unverifiable, that these scans are missing 'at random', unrelated to the values 
which would have been recorded had the scans been viable; 2) four patients only 
had clinical assessment at 24 months, but no MRI assessment: a plausible 
reason for this is that they found the scanning experience too disagreeable, so 
subsequently accepted only clinical assessment; again, though unverifiable, 
there is no strong reason to suppose that their attitude towards having a scan is 
associated with the values which would have been observed had they been 
scanned, that is, are missing not at random; 3) four patients missed the 24-month 
MRI scan, but are known to have had subsequent MRI scans and clinical 
assessments; we cannot speculate on the reason for these patients missing the 
scans, but there is again no strong reason for supposing that they are missing 
not at random; 4) finally, a further four attended neither clinical nor MRI 
assessments beyond baseline, and again there is no information on why this was 
the case; however, there is no good reason to suspect that their subsequent non-
attendance was related to the MTR values which they would have produced had 
they been scanned subsequently. 
 
Moreover, at baseline these 16 patients were very similar to the patients who 
were subsequently observed at 24 months in terms of age (missing mean 44.3, 
observed 44.7 years), gender (missing percentage female 38%, observed 36%), 
disease severity (missing MRI 24m EDSS median 5.5, observed 6) and duration 
(missing mean 3.4, observed 3.3 years), and MTR values: all the WM MTR 
values in the 16 subsequently missing patients were within 1.5% of those for the 
subsequently observed patients, except for the left visual, which was 2.5% lower 
in the 16; and for GM MTR within 2.5% of the values in subsequently observed 
patients except for left and right visual (2.7% and 3.2% lower)." 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
